BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2025 8:44:58 AM | Browse: 6 | Download: 31
 |
Received |
|
2025-03-26 03:58 |
|
Peer-Review Started |
|
2025-03-26 03:59 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-25 09:12 |
|
Revised |
|
2025-04-29 14:50 |
|
Second Decision |
|
2025-06-16 02:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-16 11:09 |
|
Articles in Press |
|
2025-06-16 11:09 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-07-11 03:52 |
|
Publish the Manuscript Online |
|
2025-07-22 08:44 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Breaking barriers: Neprilysin inhibition in chronic cardiorenal syndrome
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Olesya Ilkun and Amir Kazory |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Amir Kazory, Professor, Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, 1600 Sw Archer Rd Box 100224, Gainesville, FL 32610, United States. amir.kazory@medicine.ufl.edu |
| Key Words |
Neprilysin inhibitor; Sacubitril/valsartan; Heart failure; Chronic kidney disease; End-stage kidney disease |
| Core Tip |
Patients with advanced chronic kidney disease and end-stage kidney disease face disproportionally high rates of heart failure and mortality. Currently, there is an unmet need for medical therapies for heart failure in these populations. This review summarizes information regarding the safety and efficacy of the use of angiotensin receptor/neprilysin inhibition in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease or end-stage kidney disease to help guide safe clinical management. |
| Publish Date |
2025-07-22 08:44 |
| Citation |
<p>Ilkun O, Kazory A. Breaking barriers: Neprilysin inhibition in chronic cardiorenal syndrome. <i>World J Cardiol</i> 2025; 17(7): 107539</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i7/107539.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i7.107539 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
